CSIMarket
 
Corcept Therapeutics Inc  (CORT)
Other Ticker:  
 
 
Price: $25.1900 $0.44 1.778%
Day's High: $25.69 Week Perf: 1.78 %
Day's Low: $ 25.19 30 Day Perf: 4.31 %
Volume (M): 845 52 Wk High: $ 34.28
Volume (M$): $ 21,293 52 Wk Avg: $25.76
Open: $25.43 52 Wk Low: $20.87



 Market Capitalization (Millions $) 2,827
 Shares Outstanding (Millions) 112
 Employees 289
 Revenues (TTM) (Millions $) 482
 Net Income (TTM) (Millions $) 106
 Cash Flow (TTM) (Millions $) 69
 Capital Exp. (TTM) (Millions $) 0

Corcept Therapeutics Inc
Corcept Therapeutics Inc. is an American pharmaceutical company that is focused on the discovery, development, and commercialization of drugs that target cortisol to treat severe metabolic, oncologic, and psychiatric disorders.

The company was founded in 1998 by Dr. Joseph Belanoff and is headquartered in Menlo Park, California. Its primary drug is mifepristone, which is an oral medication that is used to treat Cushing's Syndrome, a rare hormonal disorder that is caused by the overproduction of cortisol. Mifepristone has been FDA-approved since 2012 and is marketed under the brand name Korlym.

In addition to Korlym, Corcept has a pipeline of proprietary drugs, including CORT125134, CORT118335, and CORT125281 that are currently in various stages of clinical development. These drugs target several different indications, such as triple-negative breast cancer, ovarian cancer, and Cushing's Syndrome.

Corcept has a seasoned management team that has extensive experience in the biopharmaceutical industry. The company is led by Dr. Joseph Belanoff, who serves as its Chief Executive Officer and President. He co-founded the company and has a long history of working in the field of psychiatry and endocrinology. The company's Chief Medical Officer is Dr. Paris Panayiotopoulos, who has over 25 years of experience in clinical development and is responsible for overseeing the clinical development of Corcept's drug candidates.

Corcept has a strong intellectual property portfolio, with numerous patents and patent applications that cover its proprietary drugs and technologies. The company also has collaborations with several academic institutions and research organizations to advance its drug development programs.

In 2020, Corcept reported total revenues of $421 million and had a net income of $230.4 million. The company has a market capitalization of approximately $6 billion as of August 2021 and is publicly traded on the NASDAQ stock exchange under the ticker symbol CORT.


   Company Address: 149 Commonwealth Drive Menlo Park 94025 CA
   Company Phone Number: 327-3270   Stock Exchange / Ticker: NASDAQ CORT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Corcept Therapeutics Inc

Corcept Therapeutics Inc. achieves remarkable 31.39% revenue surge, igniting unprecedented growth in Q4 2023!

Corcept Therapeutics Incorporated (NASDAQ: CORT) has just reported some incredibly exciting news that is sure to have a significant impact on the company's future success. The company's income per share for the fourth quarter of 2023 surged by an impressive 93.66% to $0.30 per share, compared to the same period last year. This growth was driven by a substantial increase in revenue of 31.39% to $135.41 million.
What's especially impressive about these results is that Corcept Therapeutics outperformed virtually all of its industry counterparts in terms of top-line growth. While the average revenue increase for Major Pharmaceutical Preparations companies in the fourth quarter of 2023 was just 3.00%, Corcept's revenue growth far surpassed that at 31.39%. This demonstrates that Corcept is not only growing at a faster rate than its peers but also leading the way in the industry.
Furthermore, the company's net earnings for the fourth quarter of 2023 increased by a staggering 88.36% to $31.161 million, compared to the same period last year. This significant rise in profitability is a clear indicator of Corcept's strong financial performance and efficient operations.

Product Service News

Groundbreaking Study Reveals High Prevalence of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes: Corcept Therapeutics Takes the Lead in Unraveling the Puzzle.

Published Thu, Feb 15 2024 9:02 PM UTC

Corcept Announces Preliminary Results from Prevalence Phase of CATALYST Clinical TrialCorcept Therapeutics Incorporated (NASDAQ: CORT), a pioneering company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders, has released promising preliminary results from the prevalence phase of its CATALYST study. This o...

Management Changes

Corcept Therapeutics Appoints Roberto Vieira as President, Oncology amidst Recent Stock Dip

Published Mon, Jan 29 2024 1:01 PM UTC


Combining Articles:
Corcept Therapeutics Incorporated, a leading commercial-stage company specializing in the discovery and development of medications to address severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol hormone effects, has appointed Roberto Vieira as the new President of Oncology. The announcement was made on Janu...

Shares

Corcept Therapeutics: Strong Financial Results, Promising Revenue Guidance, and Stock Repurchase Program Showcase Confidence in Future Growth

Published Mon, Jan 8 2024 1:01 PM UTC

Corcept Therapeutics Reports Strong Financial Results and Promising Revenue Guidance for 2024 as the Company Announces Stock Repurchase Program
In a recent press release, Corcept Therapeutics Incorporated (NASDAQ: CORT) announced its preliminary, unaudited financial results for the quarter and year ended December 31, 2023. The company, which is engaged in the discovery a...

Corcept Therapeutics Inc

Spectacular Double-Digit Revenue Surge at Corcept Therapeutics Inc. Outshines Major Pharmaceutical Sector in Recent Fiscal Epoch

Corcept Therapeutics Inc Shows Promising Financial Performance and Stock Growth
Corcept Therapeutics Inc, a leading pharmaceutical company, has reported positive financial results for the most recent fiscal period, highlighting strong revenue growth and an improvement in profitability. The company's revenue for the period reached an impressive $117.72 million, reflecting a year-on-year increase of 13.86%. Additionally, earnings per share (EPS) were $0.25, a rise of 78.57% from the preceding reporting season.
Outperforming its sector peers, Corcept Therapeutics Inc demonstrated substantial revenue growth when compared to the Major Pharmaceutical Preparations sector, which recorded a growth rate of 3.96% during the same period. This achievement underscores the company's strong market position and its ability to generate increased sales.






 

Corcept Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Corcept Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Corcept Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com